Poliovirus vaccine inactivated - Intravacc/WHO

Drug Profile

Poliovirus vaccine inactivated - Intravacc/WHO

Alternative Names: Inactivated poliovirus vaccine - IntraVacc/WHO; Poliovirus vaccine-Sinovac-Biotech; Sabin inactivated polio vaccine - Sinovac; Sabin IPV-Intravacc/WHO; Sabin IPV-Sinovac-Biotech; sIPV

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Intravacc; National Institute of Public Health and the Environment; World Health Organization
  • Developer National Institute for Public Health and the Environment; Sinovac Biotech
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Poliomyelitis

Most Recent Events

  • 28 Nov 2016 Phase-II clinical trials in Poliomyelitis (Prevention, In infants) in China (IM)
  • 21 Oct 2016 Sinovac Biotech plans a phase II and phase III trials for Poliomyelitis (IM, Injection) in China
  • 19 Oct 2016 Phase-I clinical trials in Poliomyelitis (Prevention, In infants, In children, In adults) in China (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top